BZO-CHMOXIZID explained

BZO-CHMOXIZID (CHM-MDA-19) is a synthetic cannabinoid compound first reported in 2008 in the same series as the better known derivative MDA-19.^[1] It started to be widely sold as an ingredient in grey-market synthetic cannabis blends in 2021 following the introduction of legislation in China which for the first time introduced general controls on various classes of synthetic cannabinoids,^[2] but did not include the group to which MDA-19 and BZO-CHMOXIZID belong. While BZO-CHMOXIZID is the most potent compound at CB₁ from this so-called "OXAZID" series, it is still markedly CB₂ selective and of relatively low potency at CB₁, with an EC₅₀ of 84.6 nM at CB₁ compared to 2.21 nM at CB₂.^{[3] [4]}

Legality

In the United States, As of May 22, 2023 BZO-CHMOXIZID is legal at the federal level, but may be considered illegal if intended for human consumption under the federal analogue act.^[5]

North Dakota has placed BZO-CHOMXIZID (CHM-MDA-19) (along with BZO-HEXOXIZID (MDA-19), BZO-POXIZID (Pentyl MDA-19), 5F-BZO-POXIZID (5F-MDA-19) and BZO-4en-POXIZID (4en-pentyl MDA-19) into Schedule I on 04/27/23.^[6]

In China, the May 2021 ban on specific synthetic cannabinoid core classes does not include the class of cannabinoids BZO-CHMOXIZID belongs to.^{[7] [8]}

Notes and References

1. Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M . Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain . Journal of Medicinal Chemistry . 51 . 16 . 4932–47 . August 2008 . 18666769 . 10.1021/jm8002203 .
2. Web site: 12 May 2021 . 关于将合成大麻素类物质和氟胺酮等18种物质列入《非药用类麻醉药品和精神药品管制品种增补目录》的公告 . Announcement on the inclusion of 18 substances including synthetic cannabinoids and fluamine in the "Additional Catalogue of Controlled Varieties of Non-medicinal Narcotics and Psychotropic Drugs" . Chinese . Ministry of Public Security of the People's Republic of China .
3. Deventer MH, Van Uytfanghe K, Vinckier IM, Reniero F, Guillou C, Stove CP . Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists . Drug Testing and Analysis . 14 . 9 . 1565–1575 . September 2022 . 35560866 . 10.1002/dta.3283 . 248777773 .
4. Lee KZ, Wang Z, Fong CY, Goh EM, Moy HY, Chan EC . Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring . Clinical Chemistry . 68 . 11 . 1436–1448 . November 2022 . 36175111 . 10.1093/clinchem/hvac138 .
5. Web site: 21 U.S. Code § 813 - Treatment of controlled substance analogues.
6. Web site: AN ACT to amend and reenact sections 19-03.1-05, 19-03.1-11, and 19-03.1-13 of the North Dakota Century Code, relating to the scheduling of controlled substances; and to declare an emergency. . Sixty-eighth Legislative Assembly of North Dakota in Regular Session . 3 January 2023 .
7. Web site: 12 May 2021 . 关于将合成大麻素类物质和氟胺酮等18种物质列入《非药用类麻醉药品和精神药品管制品种增补目录》的公告 . Announcement on the inclusion of 18 substances including synthetic cannabinoids and fluamine in the "Additional Catalogue of Controlled Varieties of Non-medicinal Narcotics and Psychotropic Drugs" . Chinese . Ministry of Public Security of the People's Republic of China .
8. Web site: Details for Country CHINA .